Sign in
CompletedNo phase

Impact of Susceptibility to Placebo on the Effect of Transcranial Direct Current Stimulation (tDCS) in Fibromyalgia

Key facts

Who runs it
Hospital de Clinicas de Porto Alegre
Where
Brazil1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
100 people enrolled
Started
16 Sept 2021
Ended
20 Jun 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • s-tDCS
  • a- tDCS
Record updated
8 January 2026

Who can take part

Age
18 years to 65 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Women aged 18 to 65 years; who can read and write, with a confirmed diagnosis of FM according to the American College of Rheumatology criteria (2010-2016). Pain score equal to or greater than six on the Numerical Pain Scale (NPS 0-10) on most days of the last 3 months

Who cannot take part

  • Residing outside the greater Porto Alegre area and pregnancy. Contraindications to TMS and tDCS: metallic implant in the brain; medical devices implanted in the brain, cardiac pacemakers; cochlear implant; history of alcohol or drug abuse in the last 6 months; neurological pathologies; hx of head trauma or neurosurgery; decompensated systemic diseases and chronic inflammatory diseases (lupus, rheumatoid arthritis, Reiter's syndrome); uncompensated hypothyroidism; personal history of cancer, past or undergoing treatment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Fibromyalgia (FM) is a syndrome characterized by generalized musculoskeletal pain, fatigue, non-restorative sleep, cognitive changes, depressive and neurovegetative symptoms. It is known that conventional pharmacological therapies produce responses with little clinical impact in more than 50% of patients. Functional alterations of the motor cortex and its connections with subcortical structures have also been demonstrated in FM. Based on the above, the objective of this research is to identify subgroups of patients with greater potential for responsiveness to treatment with a view to advancing diagnosis and treatment. In this study, the therapeutic target will be transcranial direct current stimulation (tDCS) according to the potential of responsiveness to the placebo effect, with the precise location of the stimulation area by a neuronavigation system, with the objective of counter-regulating the dysfunctional processes responsible for triggering and maintaining FM symptoms. Therefore, this clinical trial aims to compare the efficacy of anodal tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) compared to simulated tDCS in FM, according to susceptibility to placebo effect and serum endorphin levels.

The 2 groups in the trial

  • Respondres placebo effectPlacebo, for comparison

    Intervention: 'Transcranial Direct Current Stimulation - tDCS * The patients will receive tDCS stimulation treatment prefrontal cortex dorso lateral * According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4. * Placebo stimulation uses a 2 milliamperes current during in the first minutes, in the 10 min and in 19 minutes.

    Treatment: s-tDCS and a- tDCS

  • No respondres placebo effectExisting treatment, for comparison

    Intervention: 'Transcranial Direct Current Stimulation - tDCS * The patients will receive tDCS stimulation treatment prefrontal cortex dorso lateral * According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4. * Active stimulation uses a 2 milliamperes current during 20 minutes.

    Treatment: s-tDCS and a- tDCS

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Susceptibility to Placebo on the Effect of Transcranial Direct Current Stimulation (tDCS) in Fibromyalgia: a Randomized Clinical Trial With Extended Home Stimulation
Publications
Record updated
8 January 2026